Ser430

Site Information
LIAGGGssCsPVLsR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2020881

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 ) , mutation of modification site ( 3 ) , phospho-antibody ( 3 ) , western blotting ( 3 )
Disease tissue studied:	leukemia ( 8 ) , chronic myelogenous leukemia ( 8 ) , lung cancer ( 5 , 6 ) , non-small cell lung cancer ( 5 , 6 ) , non-small cell lung adenocarcinoma ( 5 , 6 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection] ( 7 ) , 293 (epithelial) ( 1 , 3 , 4 ) , K562 (erythroid) ( 8 ) , NCI-H1651 (pulmonary) ( 6 ) , NCI-H2073 (pulmonary) ( 5 )

Downstream Regulation
Effects of modification on Huntingtin:	protein stabilization ( 3 )

References
1	Huang B, et al. (2015) Scalable production in human cells and biochemical characterization of full-length normal and mutant huntingtin. PLoS One 10, e0121055 25799558 Curated Info
2	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
3	Dong G, et al. (2012) Mass spectrometric identification of novel posttranslational modification sites in Huntingtin. Proteomics 12, 2060-4 22623107 Curated Info
4	Mulhern D (2011) CST Curation Set: 12838; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
5	Rikova K (2011) CST Curation Set: 11015; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
6	Rikova K (2011) CST Curation Set: 11020; Year: 2011; Biosample/Treatment: cell line, NCI-H1651/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
7	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
8	Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info